Rene Castillo, M.D.

Education
Fellowship in Hematology/Medical Oncology
Cornell Medical Center, New York, NY
Chief Fellow in Hematology/Medical Oncology
Cornell Medical Center, New York, NY
Chief Resident in Internal Medicine
St Luke’s/Roosevelt Hospital Center, New York, NY
Internship & Residency in Internal Medicine
St Luke’s/Roosevelt Hospital Center, New York, NY
Rotating Internship
Dr. Manuel Gea Gonzales General Hospital, Mexico City, MX
Medical Degree
Universidad La Salle Medical School, Mexico City, MX

Medical Practice
Physician, Hematology/Medical Oncology, Texas Oncology Central Austin, Austin, Texas (2008-Present)
Physician, Hematology/Medical Oncology, Southwest Regional Cancer Center, Austin, Texas (2006-2008)
Physician, Hematology/Medical Oncology, Ochsner Clinic Foundation, New Orleans, Louisiana (1998-2006)
Louisiana Blood Bank, New Orleans, Louisiana (1989-1991)
Social Services—Research, National Cancer Institute, Mexico City, MX (1987-1989)

Research Interest
A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Drug A With and Without Drug B in the First-line Treatment of Subject With Metastatic Colorectal Cancer
Phase II, Multicenter, Open-Label, Non-Randomized Study of Intravenous Drug A Q 3 Weeks in Patients with Metastatic Breast Cancer Progressing After Therapy with Drug B, Drug C, and Drug D
A Phase III Trial of Novel Drug A Plus Drug B versus Drug B Alone in Patients with Advanced Breast Cancer Previously Treated with or Resistant to a Drug C and who are Drug D Resistant
Randomized Trial of Plus Chemotherapies in Metastatic Breast Cancer in 1st and 2nd Line Patients
A Randomized, Open-label Trial Comparing Drug A and Drug B Drug-based Treatment Regimens for the First-line Treatment of Metastatic Colorectal Cancer (mCRC)
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, randomized Clinical Trial To Evaluate The Efficacy Of Drug A In Combination With Drug B Compared With Drug A Alone For Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure Of Standard First-Line Chemotherapy
Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Drug A 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route versus Drug A Drug 0.25 mg IV for the Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting in Patients with Cancer.
A Phase IV Open Label Trial Using Drug A for Re-treatment of Multiple Myeloma Patients Following an Initial Response to Drug B
A Randomized Phase II Comparative Study of Drug A and Drug B Second-Line Therapy for Patients with Resistant and Refractory Small Cell Lung Cancer
A Dual-cohort, Perspective, Observational Study of Unresectable Stage IIIB/IV Non-small Cell Lung Cancer Patients with and without Bone Metastasis

Accolades & Memberships
“Best Doctors in America,” Best Doctors Database
“Top Doctors in New Orleans,” New Orleans Magazine
Community of Caring Award, Ochner Clinic Foundation New Orleans, Louisiana
Texas Medical Association
Travis County Medical Society
American College of Physicians
American Medical Association
American Society of Clinical Oncology
American Society of Hematology
New York State Society of Internal Medicine
North Central Cancer Treatment Group
Eastern Cooperative Oncology Group
Radiation Treatment Oncology Group
National Surgical Adjuvant Breast & Bowel Project

Rene Castillo, M.D. practices at:

• Austin South
• Cedar Park
• San Marcos